GlassScriptPhysician profile
Thomas J Raimondo
NPI 1245236918
$8,217.59
in general payments reported to CMS, 2019-2025
27 companies · $2,062 in 2025
The $2,062 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $348 · 2021: $220 · 2022: $938 · 2023: $1,927 · 2024: $2,383 · 2025: $2,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,227 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,226.50 |
| Education | $145.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,224.78 | 2022-2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $1,486.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,309.38 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $408.59 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $324.00 | 2023-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.58 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Amgen INC. | $313.32 | 2020-2025 | Tezspire |
| Pharming Healthcare, INC. | $200.65 | 2022-2025 | Ruconest |
| Csl Behring | $175.73 | 2023-2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $172.26 | 2024-2025 | Dupixent |
| Pfizer INC. | $169.06 | 2023-2025 | |
| Verona Pharma, INC. | $155.34 | 2025 | Ohtuvayre |
| Hikma Pharmaceuticals USA | $134.37 | 2019-2020 | |
| Mylan Specialty L.P. | $116.40 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $93.31 | 2019-2025 | Zerbaxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $90.92 | 2025 | |
| Astellas Pharma US INC | $83.40 | 2024 | Cresemba |
| Philips North America LLC | $67.87 | 2023 | |
| Lilly USA, LLC | $66.29 | 2019-2020 | |
| Inogen, INC. | $60.85 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Ucb, INC. | $53.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.13 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $35.11 | 2022 | |
| Grifols USA, LLC | $34.66 | 2024-2025 | Prolastin-C Liquid |
| Celgene Corporation | $34.53 | 2019 | |
| Insmed, INC. | $24.21 | 2025 | Arikayce |
| Viatris Specialty LLC | $18.21 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Raimondo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.